Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines

Executive Summary

Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.


Related Content

BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines
A Quick Primer On Roche's Immuno-Oncology Assets
How To Get Ahead In The Trendy World Of Immuno-Oncology
BioNTech's Sean Marett Explains Genentech Deal Rationale
Genentech's Associate Oncology Director Talks Cancer Vaccine Challenges
Freshly Financed CureVac Seeks Partner To Keep Up In mRNA
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects
Genmab and BioNTech to take BAbs all the way in crowded immuno-oncology
Deal Watch: U.S. Pharmas Look To Europe For Partners


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts